Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

摘要: Carcinosarcomas (also known as malignant mixed mullerian tumors) are rare and highly aggressive epithelial malignancies that contain both sarcomatous carcinomatous elements. Uterine carcinosarcomas (UCs) uncommon with approximately more than 35% presenting extra uterine disease at diagnosis. Up to 90% ovarian (OCs) will have has spread beyond the ovary. Prognosis for localized stage is poor a high risk of recurrences, local distant, occurring within 1 year. The survival women advanced UC or OC worse endometrioid high-grade serous histologies. No improvement in rates been observed past few decades an overall median less 2 years. Currently, there no clear evidence establish consensus guidelines therapeutic management carcinosarcomas. Until recently, gynecological were considered subtype sarcoma treated such. However, now be metaplastic carcinomas so should endometrial high-risk carcinomas, despite lack specific data. For UCs, comprehensive approach recommended complete surgical staging followed by systemic chemotherapy patients early disease. Active agents include paraplatin, cisplatin, ifosfamide, paclitaxel. combination carboplatin-paclitaxel most commonly used regimen adjuvant setting. Adjuvant radiotherapy (external beam irradiation and/or vaginal brachytherapy) not shown any benefit but reported decrease recurrences. OCs other cancer, mainstay treatment remains cytoreductive effort followed, even stage, platinum-based chemotherapy, usually carboplatin-paclitaxel.